(BUSINESS WIRE)--iBio, Inc., a leading developer of plant-based gene expression technologies for the development and production of biologics including therapeutic proteins and vaccines, today announced that its common stock has been approved for listing on the NYSE Amex exchange. Beginning with the opening of the market on January 4, 2011, trading is expected to commence under the NYSE Amex symbol, IBIO (formerly OTC/BB:IBPM).
“Listing our shares for trading on the NYSE Amex should significantly enhance iBio’s visibility, liquidity and suitability for a more extensive investment audience,” said Robert B. Kay, Chairman and CEO of iBio, Inc. “During this past year, we achieved our targeted milestones including clinical programs with our iBioLaunch™ technology for the development of vaccines, and strategic initiatives for the production of biosimilars. We believe this listing on the NYSE Amex will help us maintain our momentum in the coming year for commercial applications of the platform for vaccines, biosimilars and biobetters.”
“We welcome iBio, Inc. to the NYSE Euronext family of listed companies," said Scott Cutler, EVP and Co-Head of U.S. Listings and Cash Execution, NYSE Euronext. "iBio, Inc. and its shareholders will benefit from the superior market quality, services and technology provided by NYSE Amex. We look forward to a strong, lasting partnership."
About iBio, Inc.
iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins – orphan biologics, biosimilars and biobetters – and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications, individualized therapies, and other applications where speed, scalability, and surge capacity are important. The iBioLaunch technology was developed for iBio by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health. Further information is available at www.ibioinc.com.
Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
“Listing our shares for trading on the NYSE Amex should significantly enhance iBio’s visibility, liquidity and suitability for a more extensive investment audience,” said Robert B. Kay, Chairman and CEO of iBio, Inc. “During this past year, we achieved our targeted milestones including clinical programs with our iBioLaunch™ technology for the development of vaccines, and strategic initiatives for the production of biosimilars. We believe this listing on the NYSE Amex will help us maintain our momentum in the coming year for commercial applications of the platform for vaccines, biosimilars and biobetters.”
“We welcome iBio, Inc. to the NYSE Euronext family of listed companies," said Scott Cutler, EVP and Co-Head of U.S. Listings and Cash Execution, NYSE Euronext. "iBio, Inc. and its shareholders will benefit from the superior market quality, services and technology provided by NYSE Amex. We look forward to a strong, lasting partnership."
About iBio, Inc.
iBio, Inc. is a biotechnology company offering its proprietary, transformative iBioLaunch technology platform for the production of biologics including therapeutic proteins – orphan biologics, biosimilars and biobetters – and vaccines. The iBioLaunch platform uses transient gene expression in green plants for superior efficiency in protein production. Advantages include significantly lower capital and process costs, and the technology is ideally suited to infectious disease applications, individualized therapies, and other applications where speed, scalability, and surge capacity are important. The iBioLaunch technology was developed for iBio by the not-for-profit Fraunhofer USA Center for Molecular Biotechnology (FCMB) during the past eight years to overcome the inadequacies of existing technologies. iBio owns the intellectual property and technology developed at FCMB, and continues to sponsor development and application of the technology for biological applications in human health. Further information is available at www.ibioinc.com.
Forward-Looking Statements
Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.
